监测地塞米松治疗的重症COVID-19患者单核细胞HLA-DR表达与CD4+T淋巴细胞计数
该研究纳入176例ICU停留至少10天并接受地塞米松治疗的重症COVID-19成人患者,于入ICU第10天检测单核细胞HLA-DR表达(mHLA-DR)与CD4+T淋巴细胞计数,评估其与28天ICU死亡率的关联。第10天多数患者两项参数均降低;低mHLA-DR与28天死亡率显著相关,多因素分析校正年龄、合并症或既往免疫抑制后aHR=2.86(95%CI 1.30-6.32,p=0.009);CD4+T细胞计数降低者aHR=2.10(95%CI 1.09-4.04,p=0.027)。两项均降低者28天死亡风险独立且显著升高(60%,aHR=4.83,95%CI 1.72-13.57,p=0.001)。作者认为可在10天地塞米松疗程结束时用临床可及的标准化免疫监测识别高死亡风险亚组,并将免疫监测整合进ICU患者 surveillance 以指导后续免疫调节策略。
要点
- 入ICU第10天(完成10天地塞米松疗程)检测mHLA-DR与CD4+T细胞计数,可识别28天ICU死亡高危亚组。
- 第10天低mHLA-DR与28天死亡率显著相关,校正年龄、合并症或既往免疫抑制后aHR=2.86(95%CI 1.30-6.32,p=0.009)。
- 第10天CD4+T细胞计数降低与28天死亡率相关,aHR=2.10(95%CI 1.09-4.04,p=0.027)。
- mHLA-DR降低且CD4低者28天死亡率60%,独立且显著升高(aHR=4.83,95%CI 1.72-13.57,p=0.001)。
- 第10天多数患者mHLA-DR与CD4两项参数均降低,提示地塞米松疗程后免疫抑制状态常见。
适用人群与场景
- 成人COVID-19患者(n=176),ICU停留至少10天并接受地塞米松治疗。
诊断标准与关键阈值
- 于入ICU第10天测量单核细胞HLA-DR表达(mHLA-DR)与CD4+T淋巴细胞计数,以评估与28天ICU死亡率的关联。
研究设计与关键结果
- 研究类型:对176例ICU停留至少10天、接受地塞米松治疗的成人COVID-19患者进行生物标志物与28天ICU死亡率关联分析。
- 第10天多数患者mHLA-DR与CD4+T细胞计数均降低。
- 低mHLA-DR与28天死亡率显著相关,多因素分析校正年龄、合并症或既往免疫抑制后aHR=2.86(95%CI 1.30-6.32,p=0.009)。
- CD4+T细胞计数降低与28天死亡率相关,aHR=2.10(95%CI 1.09-4.04,p=0.027)。
- mHLA-DR降低且CD4低者28天死亡率为60%,独立且显著升高(aHR=4.83,95%CI 1.72-13.57,p=0.001)。
证据类型、等级与局限
- 证据类型:对176例重症COVID-19患者的生物标志物关联分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,使用临床实践中可及的标准化免疫监测工具,可在10天地塞米松疗程结束时识别高死亡风险亚组。
- 作者认为,应将免疫监测整合进ICU患者 surveillance,以指导后续免疫调节策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A 10-day dexamethasone regimen has emerged as the internationally adopted standard-of-care for severe COVID-19 patients. However, the immune response triggered by SARS-CoV-2 infection remains a complex and dynamic phenomenon, leading to various immune profiles and trajectories. The immune status of severe COVID-19 patients following complete dexamethasone treatment has yet to be thoroughly documented.
RESULTS: To analyze monocyte HLA-DR expression (mHLA-DR) and CD4 + T lymphocyte count (CD4) in critically ill COVID-19 patients after a dexamethasone course and evaluate their association with 28-day ICU mortality, adult COVID-19 patients (n = 176) with an ICU length of stay of at least 10 days and under dexamethasone treatment were included. Associations between each biomarker value (or in combination) measured at day 10 after ICU admission and 28-day mortality in ICU were evaluated. At day 10, the majority of patients presented decreased values of both parameters. A significant association between low mHLA-DR and 28-day mortality was observed. This association remained significant in a multivariate analysis including age, comorbidities or pre-existing immunosuppression (adjusted Hazard ratio (aHR) = 2.86 [1.30-6.32], p = 0.009). Similar results were obtained with decreased CD4 + T cell count (aHR = 2.10 [1.09-4.04], p = 0.027). When combining these biomarkers, patients with both decreased mHLA-DR and low CD4 presented with an independent and significant elevated risk of 28-day mortality (i.e., 60%, aHR = 4.83 (1.72-13.57), p = 0.001).
CONCLUSIONS: By using standardized immunomonitoring tools available in clinical practice, it is possible to identify a subgroup of patients at high risk of mortality at the end of a 10-day dexamethasone treatment. This emphasizes the significance of integrating immune monitoring into the surveillance of intensive care patients in order to guide further immumodulation approaches.
参考来源
- Monneret G, Voirin N, Richard JC, et al. Monitoring monocyte HLA-DR expression and CD4 + T lymphocyte count in dexamethasone-treated severe COVID-19 patients. Ann Intensive Care. 2024. PMID: 38762684. doi:10.1186/s13613-024-01310-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。